Condition: Myelodysplastic Syndromes · Secondary Acute Myeloid Leukemia · Chronic Myelomonocytic Leukemia · Sponsor: Heinrich-Heine University, Duesseldorf
This trial aims to find the MTD of Venetoclax when added to Fludarabin, Amsacrine and Ara-C + Treosulfan and to evaluate whether the addition of Venetoclax to sequential conditioning with FLAMSA + Treosulfan is safe for allogeneic blood stem cell transplantation in patients with high-risk MDS, CMML or sAML (FLAMSAClax)
This description comes directly from the study's public registry record.
Guido Kobbe, Prof. Dr. · +492118116 · kobbe@med.uni-duesseldorf.de
Always discuss trial participation with your own doctor first.
| Universitätsklinikum Aachen - Med. Klinik IV | Aachen, North Rhine-Westphalia, Germany | Recruiting |
| Universitätsklinikum Düsseldorf - Klinik für Hämatologie, Onkologie und Klinische Immunologie | Düsseldorf, North Rhine-Westphalia, Germany | Recruiting |
| Universitätsklinikum Köln Klinik I für Innere Medizin | Cologne, Germany | Recruiting |
| Universitätsklinikum Frankfurt Medizinische Klinik II | Frankfurt, Germany | Recruiting |
| Universitätsklinikum Jena - Klinik für Innere Medizin II | Jena, Germany | Recruiting |
| Klinikum rechts der Isar der TU München Klinik und Poliklinik für Innere Medizin III | München, Germany | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05807932